Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study
Le Zhang, Jun Li, Hanlin Yin, Dandan Chen, Yuan Li, Liyang Gu, Yakai Fu, Jie Chen, Zhiwei Chen, Shaoying Yang, Shuang Ye, Ting Li, Liangjing Lu
Abstract
Figure 1 Enrolment and primary outcome (N=14) (A), summary of adverse events (N=14) (B) and changes of inflammatory cytokines in the 24week study (N=9) (C).GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; LEF, leflunomide; MTX, methotrexate; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.
Topics & Concepts
MedicineTofacitinibPolymyalgia rheumaticaDermatologyInternal medicineJanus kinase inhibitorRheumatoid arthritisGiant cell arteritisVasculitisDiseaseVasculitis and related conditionsCoagulation, Bradykinin, Polyphosphates, and AngioedemaRheumatoid Arthritis Research and Therapies